Strikingly, collateral sensitivity, a feature deemed as the elevated vulnerability of resistant cells to a second therapeutic agent46, was evident in the resistant GC organoid lines when treated with SCD1 inhibitor, posing SCD1 inhibition as an exploitable molecular vulnerability to circumvent chemoresistance and cancer stemness. This evidence concerns the gene SCD and cancer.